USFDA nod to Alembic Pharma's arm Orit Labs for peptic ulcer drug 'Glycopyrrolate'
The product is a therapeutic equivalent of Casper Pharma's Robinul and Robinul Forte tablets, it added.
- Country:
- India
Drug firm Alembic Pharmaceuticals Tuesday said its subsidiary has received the US health regulator's nod for Glycopyrrolate tablets, used in the treatment of peptic ulcer.
The company's wholly owned subsidiary Orit Laboratories LLC has received approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Glycopyrrolate tablets USP in the strengths of 1 mg and 2mg, Alembic Pharmaceuticals said in a BSE filing.
The product is a therapeutic equivalent of Casper Pharma's Robinul and Robinul Forte tablets, it added.
Quoting IQVIA data, Alembic Pharmaceuticals said Glycopyrrolate tablets USP, 1 mg and 2 mg have an estimated market size of USD 15 million for 12 months ending December 2017.
The company now has a total of 81 ANDA approvals from the USFDA.
The stock was trading at Rs 617.60 apiece, up 0.32 per cent, on the BSE.
(With inputs from agencies.)
- READ MORE ON:
- Oral administration
- Route of administration
- Food and Drug Administration
- Pharmaceutical industry
- Abbreviated New Drug Application
- Owner's manual
- Craftsman
- Food
- Fast food
- US Foods
- treatment of peptic ulcer
- BSE filing
- Drug Administration
- therapeutic equivalent of Casper Pharma's Robinul
- ANDA approvals
- USFDA
- Glycopyrrolate tablets USP
- Robinul Forte tablets
- Alembic Pharma's subsidiary
- Business News
Google News